Plan B: access to emergency contraception in the legal and political cross hairs

Association of Reproductive Health Professionals, Contraception Journal, October 2013
I. Glenn Cohen, Lisa Sullivan, Eli Y. Adashi

The 8-year legal feud over access to emergency contraception between reproductive health advocates and the Food and Drug Administration (FDA) took multiple unexpected turns before coming to an abrupt end on June 10, 2013.1,2,3 On that day, after mounting legal setbacks and obstacles, the US Attorney…

Read More

Can You Buy Sperm Donor Identification?: An Experiment

Journal of Empirical Legal Studies, October 23, 2013
I. Glenn Cohen and Travis G. Coan

In the United States, most sperm donations are anonymous. By contrast, many developed nations require sperm donors to be identified, typically requiring new sperm (and egg) donors to put identifying information into a registry that is made available to a donor-conceived child once he or she reaches…

Read More

Perceptions of Efficacy, Morality, and Politics of Potential Cadaveric Organ Transplantation Reforms

Law and Contemporary Problems, Forthcoming
Christopher T. Robertson, David V. Yokum, and Megan S. Wright

We sought to explore the political feasibility of potential policy reforms to address the shortage of cadaveric organs for transplantation in America. We recruited 730 human subjects from an online population and assigned them to writing tasks that experimentally manipulated the salience of moral…

Read More

Anonymity, the Production of Goods, and Institutional Design

Fordham Law Review, Forthcoming
Jeffrey Skopek

Abstract: In this article, I demonstrate that anonymity has been misconceived as an aspect of privacy, and that understanding this mistake reveals a powerful and underutilized set of legal tools for facilitating and controlling the production of information and other social…

Read More

Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing

Boston College Law Review, forthcoming
W. Nicholson Price II

Abstract:   Drug recalls, contamination events, and shortages are on the rise, but drug companies still rely on decades-old manufacturing plants and processes. Contrary to widespread perceptions, drug manufacturing is typically expensive, inefficient, and non-innovative.…

Read More

When Truth Cannot Be Presumed: The Regulation of Drug Promotion under an Expanding First Amendment

Boston University Law Review, 2014
Christopher T. Robertson

Abstract:       The Food, Drug, and Cosmetic Act (“FDCA”) requires that, prior to marketing a drug, the manufacturer must prove that it is safe and effective for the manufacturer’s intended uses, as shown on the proposed label.…

Read More

The Globalization of Health Care: Legal and Ethical Issues

Oxford University Press, 2013
I. Glenn Cohen, ed. (Faculty Director)

The Globalization of Health Care: Legal and Ethical Issues, edited by I.…

Read More

Do Damages Caps Reduce Medical Malpractice Insurance Premiums?: A Systematic Review of Estimates and the Methods Used to Produce Them

Research Handbook on the Economics of Torts, Edward Elgar Publishers, November 21, 2012
Kathryn Zeiler (Academic Fellow Alumna) & Lorian Hardcastle

Abstract:       Despite common claims made in policy debates, the theoretical connection between tort reform and medical malpractice insurance premiums is ambiguous. Simple models suggest reforms such as statutory damages caps reduce premiums. More elaborate models…

Read More